Neurological biomarkers are detectable substances majorly found in the cerebrospinal (CSF) fluid when there has been some damage to the brain. These biomarkers help in early diagnosis of neurological disorders, drug development, and for developing personalized medicine. However, the growing research and discovery in the field of neurology has enabled the introduction of novel methods for detection and better treatment of neurological disorders such as Alzheimer’s, Schizophrenia, Parkinson’s disease, and others. For instance, according to an article in Science Journal published by the American Association for the Advancement of Science in December 2017, researchers at the University Of Arizona College Of Medicine, Tucson, used neurological biomarkers to study the immunological response of the body to the dead brain tissue after stroke. The process of removal of dead brain tissue by the immune system is known as liquefactive necrosis. Neurological biomarkers play a crucial role in monitoring the progress of liquefactive necrosis to prevent neurotoxicity.
Global Neurological Biomarkers Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.
According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 177,866,160 cases and 3,857,974 deaths due to coronavirus disease (COVID-19) were reported till June 20, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Neurological Biomarkers
The COVID-19 pandemic and the lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. Biotechnology industry is one such sector which has been majorly impacted by the pandemic.
The COVID-19 pandemic has impacted the entire supply chain of the biotechnology industry mainly due to strict lockdown in several regions. However, the demand for neurological biomarkers is expected to increase during the pandemic due to association of neurological conditions with COVID-19 infection.
According to an article published by Alzheimer's Research & Therapy journal in June 2021, a study by Cleveland Clinic, revealed a close relationship between coronavirus genes and neurological disorder such as Alzheimer’s disease. The study showed that SARS-CoV-2 infection led to several pathways related to neuroinflammation and brain microvascular injury, which may lead to cognitive impairment as well. Thus, impact of the coronavirus (COVID-19) pandemic is expected to fuel the growth of the global neurological biomarkers market during the forecast period, owing to rising neurological disorders as a result of COVID-19 infection during the pandemic.
The global neurological biomarkers market is estimated to be valued at US$ 8,979.6 Mn in 2021, and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).
|Base Year:||2020||Market Size in 2021:||US$ 8,979.6 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||14.7%||2028 Value Projection:||US$ 23,453.2 Mn|
Abbott Laboratories, QIAGEN N.V., Myriad RBM, Thermo Fisher Scientific Inc., Athena Diagnostics, Bio-Rad Laboratories, Inc., AbaStar MDx, Inc., Acumen Pharmaceuticals, Banyan Biomarkers, Inc., Alseres Pharmaceuticals, Inc., Proteome Sciences, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, and Psynova Neurotech
|Restraints & Challenges:||
Figure 1: Global Neurological Biomarkers Market Share (%) Analysis, By Biomarker Type, 2021
The rising cases of neurological and psychiatric disorders is the major factor that is expected to drive the neurological biomarkers market growth over the forecast period.
The rising number of neurological and psychiatric disorders cases is expected to drive growth of neurological biomarkers market over the forecast period. According to Alzheimer's Disease Facts and Figures Report, in 2019, more than 5.8 million people in America were suffering from dementia associated with Alzheimer’s disease, out of which most of the patients were above the age of 75 years.
Moreover, increasing number of research and development activities for improving the effectiveness of neurological biomarkers is expected to aid in the growth of the market over the forecast period. For instance, an observational research study was initiated by Massachusetts General Hospital, U.S., in 2018, and is expected to be completed by August 2022. This study aims to investigate neuroimaging biomarkers, which are linked to the prognosis of Functional Neurological Disorder (FND).
In addition, rising product launch and approval is expected to show exponential growth of neurological biomarkers over the forecast period. For instance, in 2017, Quanterix Corp., an American diagnostic tool company, launched its product Simoa N4PA assay, which can detect up to four neurological biomarkers- NF-L, Tau, GFAP, and UCH-L1. Moreover, in 2018, Abcam Plc., a global life sciences company that supplies protein research tools, launched its product FirePlex HT Immunoassay for rapid detection of neurological biomarkers.
Global Neurological Biomarkers Market – Restraints
However, growth of the neurological biomarkers market may be hampered, owing to lack of specificity and reliability of some neurological biomarkers. According to a study published in Future Medicine Journal in 2019, CSF DJ-1 that is used as a neurological biomarker for Parkinson’s disease, showed inconsistent results and lack of specificity.
Global Neurological Biomarkers Market – Regional Analysis
On the basis of region, the global neurological biomarkers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global neurological biomarkers market over the forecast period, owing to rising government initiatives for management of neurological disorders. This is expected to drive the growth of the global neurological biomarkers market over the forecast period. For instance, the global action plan on the public health response to dementia 2017-2025 was endorsed by the World Health Assembly (WHA) in 2017 to set up a framework for increasing awareness about dementia, support the research and innovation in neuroscience, and making treatments for dementia more accessible.
Moreover the rising focus of market players in business strategies such as acquisitions, partnerships, and others are expected to fuel the growth of neurological biomarkers market over the forecast period. For instance, in 2017, Abbott laboratories, an American medical device company, acquired Alere Inc., an American diagnostic kit manufacturer, to expand its diagnostic kits business portfolio. Such acquisitions would create opportunities for neurological biomarkers as these diagnostic kits are majorly based on biomarker analysis.
Figure 2: Global Neurological Biomarkers Market Value (US$ 8,979.6 Mn), by Region, 2021
Global Neurological Biomarkers Market – Competitive Landscape
Major players operating in the global neurological biomarkers market include Abbott Laboratories, QIAGEN N.V., Myriad RBM, Thermo Fisher Scientific Inc., Athena Diagnostics, Bio-Rad Laboratories, Inc., AbaStar MDx, Inc., Acumen Pharmaceuticals, Banyan Biomakers, Inc., Alseres Pharmaceuticals, Inc., Proteome Sciences, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, and Psynova Neurotech
Neurological biomarkers are biological indicators present in the cerebrospinal fluid that can be measured to study the health of the brain. Neurological biomarkers can be of various types such as imaging biomarkers, metabolomics biomarkers, proteomic biomarkers, and genomics biomarkers. Neurological biomarkers help in the early diagnosis of neurological disorders such as epilepsy, brain tumor, Alzheimer’s, Parkinson’s disease, multiple sclerosis, and others. These biomarkers also assist in monitoring the progress of a neurological disease and studying biological response towards a treatment. Neurological biomarkers captures different characteristics of a disease such as pathogenicity and heterogeneity, which helps in the development of personalized treatment therapy. Rapid research and technological advances in the field of neurology has led to introduction of novel biomarkers that are accurate, reliable and sensitive. According to an article published by the Frontiers in Neurology Journal in January 2019, a computational analysis of gene expression data was carried out in Alzheimer’s disease patients to predict blood-based biomarkers, where the experimental validation was conducted using Enzyme Linked Immuno-sorbent Assay (ELISA) and Western blot analyses. This study led to the discovery of novel neurological biomarker- VLDLR (Very Low Density Lipoprotein Receptor) as a biomarker for Alzheimer's disease.
Market players and research organizations are conducting clinical trial studies for finding out novel neurological biomarkers, which could contribute to the growth of the market over the forecast period. For instance, a clinical study based on neurological biomarkers was initiated by IRCCS Neuromed Mediterranean Neurological Institute, Italy in March 2019, which is expected to be completed by January 2023. This study investigates the use of circulating, cell-free mitochondrial DNA (ccf-mtDNA) as a neurological biomarker for the early detection and prognosis of multiple sclerosis. Such clinical studies is expected to create opportunities for neurological biomarkers market over the forecast period.
Market players are focusing on the launch of products, which is expected to strengthen their position in the global neurological biomarkers market. For instance, in 2018, Biosensis, an Australian manufacturer of life science reagents, launched new BDNF ELISA Kit for accurate measurement of two important blood biomarkers BDNF and pro-BDNF in under four hours. Brain-derived neurotrophic factor (BDNF) biomarker is an important indicator for various neurological and psychiatric disorders such as clinical depression.
Market players are involved in expanding their presence globally, by entering into partnership with other companies in order to enhance distribution, this is expected to drive the growth of the neurological biomarkers market. For instance, in January 2017, Banyan Biomarkers, an American diagnostic tool company, entered into partnership with BioMerieux, a French biotechnology company, to validate and commercialize blood-based neurological biomarkers for in vitro diagnostics for traumatic brain injury (TBI).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients